Adenomatous Polyposis Coli

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona LONDON – Oct. 24, 2024 – Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces scientific presentations of two novel programs in its pipeline at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The presentations include data from two preclinical oncology assets, AVA6103 and AVA7100, from Avacta’s pipeline of pre|CISION® product candidates. Both presentations take place today in the Antibody Drug Conjugate (ADC) poster session at the Symposium. Avacta’s pre|CISION® product candidates are designed to be activated specifically in the tumor microenvironment (TME), thereby enabling improved antitumor activity while reducing systemic toxicities. Each peptide drug conjugate (PDC) in the Company’s pipeline is comprised of an active antitumor drug (known as a payload) linked to the pre|CISION peptide, which renders the payload inert and is cleaved only within the tumor by the action of Fibroblast Activation Protein, or FAP, expressed in the cancer associated fibroblasts in the TME. The pre|CISION® technology addresses key limitations of ADCs, namely (1) non-specific payload release that results in significant off target toxicities, and (2) the complexity of the bystander effect, which is necessary to target antigen-negative tumor cells and thus to treat antigen-low populations. The pre|CISION platform addresses these limitations by releasing payload only in the tumor microenvironment and optimizing the bystander mechanism of action. AVA6103 is a pre|CISION-enabled PDC comprised of the pre|CISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development. AVA7100 is a part of a new class of pre|CISION®-enabled Affimer® drug conjugates with potential applications in multiple cancer types, including those with lower levels of FAP in the tumor. AVA6103 and AVA7100 are expected to enter IND-enabling studies in late 2024 and 2H 2025, respectively. The details of these advances in the pre|CISION® technology are presented below. Christina Coughlin, MD PhD, CEO of Avacta, commented: “We are encouraged by the preclinical data from AVA6103 demonstrating that FAP-enabled exatecan induces DNA damage and drives cancer cell death and we look forward to advancing this promising therapy toward the clinic. The preliminary data from AVA7100 demonstrating that exposure to Affimer® Drug Conjugates (AffDCs) results in drug cleavage, release of the payload and tumor cell kill as a bystander function are exciting for this entirely new class of therapies. “These presentations showcase the evolution of our pre|CISION® platform technology to selectively deliver highly potent payloads directly to the TME, while minimizing exposure in normal tissues and optimizing patients’ outcomes. Our first program, AVA6000, demonstrates a four- to six-fold increase in the therapeutic index in the clinic and in preclinical models. With the advances in the platform, we are now seeing a 75-fold increase in therapeutic index with our recently announced exatecan program, AVA6103 in preclinical models, suggesting that AVA6103 could have an unprecedented safety profile in the clinic. Potent topoisomerase I inhibitors are the payloads of ADC therapies in the clinic, although the non-specific release of these payloads can lead to severe off-target toxicities. Given the lack of these toxicities in our first program and the broad reach of the topoisomerase I inhibitor class, we see our next programs as having great potential for true impact in patients with high unmet need.” AVA6103 Results In a poster titled “The novel peptide drug conjugate AVA6103 is a FAP-enabled pre|CISION® medicine which targets Topoisomerase I to the tumor microenvironment via FAP cleavage” in vivo data were presented that demonstrate the ability to target and accumulate the active warhead in the tumor microenvironment, resulting in tumor growth inhibition with AVA6103. Specifically, the key findings from the poster demonstrate: The therapeutic index of exatecan is significantly increased by pre|CISION enabling, specifically the maximum tolerated dose of pre|CISION exatecan (AVA6103) observed is 75 times that of conventional exatecan in a daily dosing regimenAVA6103 optimizes the bystander effect where the conjugate is only cleaved by FAP-positive fibroblasts, and released exatecan can enter FAP-negative cancer cellsHigh intratumoral warhead concentrations are seen at 4hr and 24hr timepoints for several pre|CISION exatecan compounds, with up to 50-fold higher warhead concentrations in the tumor versus plasma in a patient-derived xenograft model, AVA6103 inhibits tumor growth, with complete responses noted in a preclinical treated model engineered with human FAP expression (HEK-FAP) tumors. Increased survival was also shown in this model treated with AVA6103 compared with other models with vehicle-treated tumors. AVA7100 Results A poster titled “Affimer® Drug Conjugates (AffDC) targeting Fibroblast Activation Protein-α deliver highly toxic warheads to the tumor microenvironment by leveraging the pre|CISION® release mechanism” include data demonstrating that exposure of tumor cell line or fibroblast cell co-cultures to AffDCs results in drug cleavage, release of the warhead and tumor cell kill as a bystander function. Specifically, the key findings from the poster demonstrate: With non-internalizing Affimer protein binding and extracellular warhead release by FAP, the AffDC optimizes the bystander effect, leading to effective killing of antigen-positive and antigen-negative tumor cellsAffDCs have an antigen-binding region of 14kDa (single-domain) or 28 kDa (two-domain) that is 10-20% of the size of an antibody, optimizing tumor penetration. AffDCs may be rapidly engineered for optimal biophysical and functional characteristics.The FAP AffDC molecules exhibit a broad range of FAP binding (including potency up to single-digit picomolar, pM) combined with highly tumor-specific warhead release by leveraging the preCISION linker to release warhead directly in the tumor microenvironment and target that delivery to tumors with low FAP expression For further information from Avacta Group plc, please contact: Avacta Group plcMichael Vinegrad, Group Communications Directorhttps://avacta.com/Peel Hunt (Nomad and Broker)James Steel / Chris Golden / Patrick Birkholmwww.peelhunt.comICR Consilium Mary-Jane Elliott / Jessica Hodgson / Sukaina Virjiavacta@consilium-comms.com About the pre|CISION® Platform The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients. About AVA6000: FAP-enabled doxorubicin The lead pre|CISION® program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/. AVA6103: FAP-enabled PDC targeting Topoisomerase I AVA6103 is a pre|CISION-enabled PDC comprised of the pre|CISION peptide linked to exatecan, the most potent topoisomerase I inhibitor in clinical development. Exatecan has demonstrated clinical activity in breast, gastric, lung and pancreatic cancers; however, it is associated with severe dose-limiting toxicities and a short half-life in patients that led to discontinuation of its monotherapy development. AVA6103 is designed to enable patients to obtain the therapeutic benefit associated with exatecan, while limiting the systemic exposure associated with its poor tolerability. AVA7100: pre|CISION® FAP Affimer Drug Conjugate (AffDC) AVA7100 is a pre|CISION®-enabled Affimer® drug conjugate, a new class of therapies being developed by Avacta with potential applications in a variety of cancer types, including those with lower levels of FAP in the tumor. Affimer® molecules are small proteins that are engineered to bind to a target molecule in the same way that an antibody does, but with several advantages, including smaller molecule size and a broad range of binding affinity. AVA7100 consists of a novel FAP-Affimer conjugated to a pre|CISION-peptide linker with multiple options for the payload. About Avacta Group plc - https://avacta.com/ Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. Its clinical stage oncology biotech division Avacta Therapeutics is harnessing the proprietary pre|CISION® platform technology to develop novel, highly targeted cancer drugs. Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics. To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/.

SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- The Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT) applauds the National Comprehensive Cancer Network (NCCN) for recent updates to its Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric practice guidelines that expand access to hereditary cancer genetic testing for individuals and their families impacted by colorectal, endometrial and gastric cancers. Previous updates expanded the recommendation for genetic testing to all patients with colorectal cancer diagnosed under age 50 and suggested genetic testing be considered for all patients diagnosed over age 50, regardless of family history. The updated guidance, released on August 8, 2024, makes several key changes regarding who should receive hereditary cancer genetic testing, including: Testing should be considered for all patients diagnosed with endometrial cancer after age 50 regardless of their family history of cancer Testing is now recommended for all individuals with a close relative with adenomatous polyposis who is unavailable for testing Testing is now recommended for all patients diagnosed with diffuse gastric cancer, regardless of age at diagnosis or family history of cancer The updated guidelines also include new recommendations on which genes should be tested for colon and endometrial cancers. NCCN Guidelines are important because they provide evidence-based, consensus-driven recommendations for cancer care in the United States. Developed by multidisciplinary, disease- and issue-specific clinicians and researchers, these guidelines assist clinicians in decision-making, inform the development of treatment protocols, and influence insurance coverage. "We are thrilled to see the NCCN's updated guidelines, which significantly expand access to hereditary cancer genetic testing for patients with endometrial and gastric cancers," says Lisa Schlager, Vice President of Public Policy for FORCE: Facing Our Risk of Cancer Empowered. "By broadening the eligibility criteria for genetic testing, we can better identify those at risk and provide them with the necessary tools to manage their health proactively. This update aligns perfectly with INTERACT's mission to promote evidence-based access to genetic testing and improve outcomes for patients with hereditary cancers." INTERACT, a coalition dedicated to increasing evidence-based access to genetic testing for people with or at risk of hereditary cancers, works to drive awareness and inform changes that will equalize access for those whose outcomes could benefit most from genetic testing. Hereditary cancer genetic testing has been shown to improve outcomes by identifying those most at risk and informing management strategies. Laboratory members of the coalition include Ambry Genetics, Illumina, Myriad Genetics, Natera and Quest Diagnostics. Patient advocacy organization members include AliveAndKickn, FORCE, the Ovarian Cancer Research Alliance, Let's Win Pancreatic Cancer and ZERO Prostate Cancer. The coalition seeks to provide a collective voice in support of the progression of medical professionals and industry guidelines for genetic testing for inherited mutations that increase cancer risk. About INTERACT The mission of INTERACT is to bring together specialized genetic testing laboratories and patient advocacy groups to support the progression and evolution of medical policy and industry guidelines for cancer genetic testing. Our members are recognized institutions in cancer genetics. Current commercial members include Ambry Genetics, Illumina, Myriad Genetics, Natera and Quest Diagnostics. Advocacy members include AliveAndKickn and FORCE: Facing Our Risk of Cancer Empowered, the Ovarian Cancer Research Alliance, Let's Win Pancreatic Cancer and ZERO Prostate Cancer. We seek to develop the evidence base and rationale to inform changes in cancer-related genetic testing policies to expand patient access to evidence-based testing. For more information, visit: Media Contact: [email protected] SOURCE INTERACT Coalition WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Exhibit 99.1 October 15, 2024 Biodexa Announces Successful Appeal of Nasdaq Delisting Biodexa Pharmaceuticals PLC. (the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that a Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for an extension of time to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq Stock Market LLC (“Nasdaq”) set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). As a condition of the Panel’s decision, the Company is required to demonstrate compliance with the Minimum Bid Price Requirement by evidencing a closing bid price of at least $1.00 per share for a minimum of 20 consecutive trading days by October 31, 2024. About Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Blader Cancer: tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signaling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com. Forward-Looking Statements Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.